Perioperative medicine & outcomes
Exogenous Sex Hormones and Postoperative Nausea and Vomiting Risk in Transgender Patients
Authors' conclusion
Transgender female (AMAB) patients on estrogen GAHT required rescue antiemetics more often than cisgender males and cisgender females after orchiectomies and augmentation mammoplasties. Transgender male (AFAB) patients on testosterone GAHT required rescue antiemetics less often than cisgender females after hysterectomies.
Study context
- Population
- Transgender patients receiving gender-affirming hormone therapy (GAHT) and cisgender patients undergoing hysterectomy, orchiectomy or augmentation mammoplastymatched cohorts
- Participants
- 1,660 / 1,660 / 870 / 870 / 668 / 668
- Exposure
- Transgender patients on GAHT vs cisgender patients, by surgery type
- Transgender male (hysterectomy)n = 1,660
- Cisgender female (hysterectomy)n = 1,660reference
- Transgender female (orchiectomy)n = 870
- Cisgender male (orchiectomy)n = 870reference
- Transgender female (mammoplasty)n = 668
- Cisgender female (mammoplasty)n = 668reference
- Outcome
- Administration of a rescue antiemetic (droperidol, promethazine, dimenhydrinate, metoclopramide, prochlorperazine)
- Follow-up
- Day of or day following surgery
Methodological detailspropensity score matched, TriNetX database
- Propensity score matched
- TriNetX database
Main finding
As reported in the abstract
Transgender male (hysterectomy) vs Cisgender female (hysterectomy): P = 0.0227 · Transgender female (orchiectomy) vs Cisgender male (orchiectomy): P < 0.0001 · Transgender female (mammoplasty) vs Cisgender female (mammoplasty): P = 0.0005
Observational data: associations, not effects.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →